Holen Sie sich die Stockscreener-App
2.28
2.56%
-0.06
Vorhandelsmarkt:
2.23
-0.05
-2.19%
Schlusskurs vom Vortag:
$2.34
Offen:
$2.34
24-Stunden-Volumen:
81,703
Relative Volume:
0.20
Marktkapitalisierung:
$239.88M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-6.019
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
-3.39%
1M Leistung:
+18.13%
6M Leistung:
+2.01%
1J Leistung:
+26.67%
1-Tages-Spanne:
$2.265
$2.34
1-Wochen-Bereich:
$2.235
$2.47
52-Wochen-Spanne:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.28 | 248.61M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
What drives ProQR Therapeutics N.V. stock priceOutstanding capital growth - jammulinksnews.com
What analysts say about ProQR Therapeutics N.V. stockRemarkable growth - printweek.in
Owning 32% shares,institutional owners seem interested in ProQR Therapeutics N.V. (NASDAQ:PRQR), - Yahoo Finance
Is ProQR Therapeutics N.V. a good long term investmentFree Stock Selection - Jammu Links News
ProQR Therapeutics N.V. Stock Analysis and ForecastDynamic investment growth - jammulinksnews.com
Is ProQR Therapeutics N.V. stock a growth or value playTop Momentum Stock Pick - newser.com
ProQR stock rating reiterated by Cantor Fitzgerald ahead of key 2H25 data - Investing.com Nigeria
Why ProQR Therapeutics N.V. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
How ProQR Therapeutics N.V. stock performs during market volatilityProven Win Setups - Newser
What makes ProQR Therapeutics N.V. stock price move sharplyFree Wealth-Building Investment Strategies - Newser
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) high institutional ownership speaks for itself as stock continues to impress, up 16% over last week - simplywall.st
ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares Acquired by OneDigital Investment Advisors LLC - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Vontobel Holding Ltd. Invests $48,000 in ProQR Therapeutics N.V. (NASDAQ:PRQR) - Defense World
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com Australia
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles By Investing.com - Investing.com South Africa
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat
ProQR Therapeutics' (PRQR) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Market Outperform Rating at JMP Securities - Defense World
PRQR: Cantor Fitzgerald Reiterates Overweight Rating | PRQR Stoc - GuruFocus
ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target By Investing.com - Investing.com Canada
ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target - Investing.com
ProQR submits clinical trial application for RNA editing therapy By Investing.com - Investing.com India
ProQR Seeks EU Approval for Liver Cell Protein Trial - MarketScreener
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewswire
ProQR Advances First RNA Editing Therapy to Clinical Trials for Liver Disease | PRQR Stock News - Stock Titan
Bank of America Corp DE Boosts Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - simplywall.st
Equities Analysts Offer Predictions for PRQR FY2026 Earnings - MarketBeat
Research Analysts Set Expectations for PRQR FY2026 Earnings - Defense World
Jane Street Group LLC Buys Shares of 11,400 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Sold by Two Sigma Advisers LP - Defense World
Squarepoint Ops LLC Grows Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Analysts - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Increase in Short Interest - MarketBeat
ProQR Shareholders Approve Key Resolutions at Annual Meeting - TipRanks
ProQR Therapeutics (NASDAQ:PRQR) Shares Purchased by Northern Trust Corp - MarketBeat
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):